Nuclear Pharmacy Market Size, Share & Trends Analysis Report By Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals), Therapeutic Nuclear Medicine (Alpha Emitters, Beta Emitters), Brachytherapy Isotopes. By Application (Diagnostic Applications (SPECT Applications, PET Applications), Therapeutic Applications), By Region, And By Segment Forecasts, 2025-2034

The Nuclear Pharmacy Market Size is valued at USD 6.27 Bn in 2024 and is predicted to reach USD 17.96 Bn by the year 2034 at a 11.2% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

• The market is growing because technological developments have made it possible to diagnose and treat malignant tumours with radiopharmaceuticals.
• Rising government financing for nuclear medicine research and development will propel market expansion.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• A severe lack of qualified healthcare workers hinders the implementation of nuclear pharmacy methods.

The preparation, dispensing, and management of radioactive materials used in nuclear medicine operations are the focus of nuclear pharmacy, a subspecialty of pharmacy. Small quantities of radioactive substances (radiopharmaceuticals) are used in the medical speciality known as nuclear medicine to diagnose and treat various illnesses and ailments.

The need for radiopharmaceuticals was driven by the rising use of nuclear medicine procedures for diagnostic and therapeutic applications, which fueled the expansion of the nuclear pharmacy business. The need for radiopharmaceuticals was driven by the rising use of nuclear medicine procedures for diagnostic and therapeutic applications, which fueled the expansion of the nuclear pharmacy business.

However, the pandemic impacted the research and development of new radiopharmaceuticals and nuclear medical applications. The rate of innovation in the nuclear pharmacy sector may have been slowed down by limitations on research activities and the allocation of resources to the pandemic response. 

Competitive Landscape:

Some Major Key Players In The Nuclear Pharmacy Market:

• GE HealthCare
• Cardinal Health
• Curium 
• Bayer AG 
• Lantheus Holdings, Inc.
• Bracco Imaging S.p.A.
• PharmaLogic Holdings Corp.
• Eczacibasi-Monrol Nuclear Products
• NTP Radioisotopes SOC Ltd
• Nordion Inc.
• Novartis (Advanced Accelerator Application)
• NorthStar Medical Radioisotopes
• Eckert & Ziegler
• Isotope JSC
• Siemens Healthineers
• Jubilant DraxImage,Inc.
• Telix Pharmaceuticals Limited
• Mallinckrodt Pharmaceuticals
• Bracco
• IBA Worldwide
• Other Prominent Players

Market Segmentation: 

The Nuclear Pharmacy Market is segmented on the basis of type and application. Based on type, the market is segmented as Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals (Tc-99m, I-123, Tl-201, Ga-67, Other SPECT Isotopes), PET Radiopharmaceuticals (F-18, Rb-82, Other PET Isotopes)), Therapeutic Nuclear Medicine (Alpha Emitters(Ra-223), Beta Emitters (I-131, Y-90, Sm-153, Lu-177, Re-186, Other Beta Emitters)), Brachytherapy Isotopes (I-125, Ir-192, Pd-103, Cs-131), Other Brachytherapy Isotopes). The application segment includes Diagnostic Applications (SPECT Applications (Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications), PET Applications (Oncology, Cardiology, Neurology, Other PET Applications)), Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Indications).

Based On Application, The Diagnostic Nuclear Medicine Segment Is Accounted As A Major Contributor To The Nuclear Pharmacy Market

The diagnostic nuclear medicine category is expected to hold a major share of the global Nuclear Pharmacy Market in 2021. Due to factors like effective imaging of patients with numerous types of cancer, new product launches for diagnosing various illnesses, and rising procedural volumes globally, this category is also expected to rise at a significant CAGR. Imaging methods used in nuclear medicine diagnostics include planar imaging, single-photon emission computed tomography (SPECT), and positron emission tomography (PET). Each method offers distinct knowledge about the anatomy, physiology, and molecular functions of the organism. 

The Diagnostic Segment Witnessed Growth At A Rapid Rate 

The diagnostic segment division is projected to grow at a rapid rate in the global Nuclear Pharmacy Market. A wide variety of radiopharmaceuticals used in various diagnostic imaging studies are prepared and compounded by commercial nuclear pharmacies. To assure the safety and effectiveness of radiopharmaceuticals, they are prepared in a controlled setting using stringent quality control procedures. Commercial nuclear pharmacies provide support for a variety of medical imaging modalities, including planar imaging, SPECT (Single-Photon Emission Computed Tomography) and Positron Emission Tomography (PET). 

In The Region, The North America Nuclear Pharmacy Market Holds A Significant Revenue Share 

The North American, Nuclear Pharmacy Market, is expected to register the highest market share in terms of revenue in the near future. The region is likely to witness rapid acceptance of technologically advanced and effective medicinal radiopharmaceuticals, as well as an increase in the use of nuclear imaging technology.

In addition, it is anticipated that throughout the projected period, the prevalence of various cancers and other chronic conditions will contribute to the market's rise in North America. As a result of the leading companies' recent product releases and the adoption of cutting-edge radiopharmaceuticals, Europe is predicted to experience significant market expansion. Additionally, this region's market players' acquisitions and mergers are promoting regional expansion. 

Recent Developments:

• In January 2024, Cardinal Health officially signed an agreement to pay $1.2 billion in cash to acquire Specialty Networks, a multi-specialty group purchasing and practice development company powered by technology. Specialty Networks create financial and clinical value for independent specialist physicians and partners through several specialty GPOs, such as United Rheumatology, Gastrologix, GastroGPO, UroGPO, and others.

Nuclear Pharmacy Market Report Scope: